Benzinga | Sep 30, 2021 04:32PM EDT

ORIC Pharmaceuticals Announces Multiple Data Presentations At AACR-NCI-EORTC Virtual International Conference On Molecular Targets And Cancer Therapeutics

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced three poster presentations at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics to be held October 7-10, 2021.

Details of the poster presentations are as follows:

Initial results from a Phase 1b study of ORIC-101, a glucocorticoid Title: receptor antagonist, in combination with enzalutamide in patients with metastatic prostate cancer Poster P041 #: Biomarker results supporting selection of RP2D from a Phase 1b study Title: of ORIC-101, a glucocorticoid receptor antagonist, in combination with enzalutamide in patients with metastatic prostate cancer progressing on enzalutamide Poster P015 #: ORIC-114, an orally bioavailable, irreversible kinase inhibitor, has Title: superior brain penetrant properties and enhanced potency in preclinical studies of HER2-positive breast cancer Poster P234 #:

Full abstracts and poster presentations will be available for on-demand viewing via the online platform for AACR-NCI-EORTC on October 7, 2021, at 9 a.m. ET.